Pain Therapy With Pfizer’s Lyrica Yields Positive Responses

Pain Therapy With Pfizer’s Lyrica Yields Positive Responses
Researchers at Pfizer Inc. recently reported that patients with disorders related to pain such as fibromyalgia respond positively to treatment with the company’s drug Lyrica within 3 to 4 weeks. The study was published in the journal Dovepress and is entitled “Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin”. Pregabalin, marketed by Pfizer under the trade name Lyrica, is a drug indicated for the treatment of anxiety disorders and several conditions related to neuropathic pain including fibromyalgia, spinal cord injury, diabetic peripheral neuropathy (DPN; refers to nerve damage caused by diabetes) and postherpetic neuralgia (PHN; refers to nerve damage caused by herpes zoster infection). Fibromyalgia is a disorder characterized by widespread chronic musculoskeletal pain, incapacitating fatigue, stiffness and numbness in certain parts of the body, painful response to pressure, headaches, poor sleep quality, anxiety or depression and mood alterations. Fibromyalgia, spinal cord injury, DPN and PHN are all linked to chronic pain and can affect people’s ability to conduct simple daily tasks, compromising their health-related quality of life. A better understanding of the impact of pregabalin treatment in patients with these chronic pain conditions is necessary. In the study, researchers analyzed data from five randomized, placebo
Subscribe or to access all post and page content.